The landscape of allergic disease treatment is continually evolving,and a new contender,lebrikizumab,is drawing attention for its potential in managing conditions like asthma,chronic rhinosinusitis,and atopic dermatitis. You may be familiar with existing biologics like dupilumab (Nepi) and omalizumab (Novartis), which have already made significant strides in these areas, even showing
Worth a look